

KLRC1 Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP8629B

Specification

KLRC1 Antibody (C-term) - Product Information

Application Primary Accession Reactivity Host Clonality Isotype Antigen Region WB, IHC-P, FC, IF,E <u>P26715</u> Human Rabbit Polyclonal Rabbit IgG 180-206

KLRC1 Antibody (C-term) - Additional Information

Gene ID 3821

Other Names NKG2-A/NKG2-B type II integral membrane protein, CD159 antigen-like family member A, NK cell receptor A, NKG2-A/B-activating NK receptor, CD159a, KLRC1, NKG2A

Target/Specificity

This KLRC1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 180-206 amino acids from the C-terminal region of human KLRC1.

Dilution WB~~1:2000 IHC-P~~1:50~100 FC~~1:25 IF~~1:25 E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

KLRC1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

KLRC1 Antibody (C-term) - Protein Information

Name KLRC1



Synonyms NKG2A {ECO:0000303|PubMed:18083576}

Function Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class la molecules. Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self (PubMed: 18083576, PubMed: 37264229, PubMed:<u>9430220</u>, PubMed:<u>9486650</u>). Upon HLA-E-peptide binding, transmits intracellular signals through two immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHP-1 and INPPL1/SHP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules (PubMed:<u>12165520</u>, PubMed:<u>9485206</u>). Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions (PubMed: 30860984, PubMed: 9430220, PubMed:9485206, PubMed:9486650), Dominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity (PubMed:12387742). On intraepithelial CD8-positive gamma-delta regulatory T cells triggers TGFB1 secretion, which in turn limits the cytotoxic programming of intraepithelial CD8-positive alpha-beta T cells, distinguishing harmless from pathogenic antigens (PubMed:<u>18064301</u>). In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell exhaustion (PubMed: <u>30503213</u>, PubMed: <u>30860984</u>).

Cellular Location

Cell membrane; Single-pass type II membrane protein

Tissue Location

Predominantly expressed in NK cells (at protein level) (PubMed:20952657, PubMed:9430220, PubMed:9485206). Expressed in intraepithelial CD8-positive T cell subsets with higher frequency in gamma-delta T cells than alpha-beta T cells (at protein level) (PubMed:18064301). Expressed in memory gamma-delta T cells (at protein level) (PubMed:20952657). Restricted to a subset of memory/effector CD8-positive alpha-beta T cells (at protein level) (PubMed:12387742) Expressed in intratumoral NK and CD8-positive T cells (PubMed:30503213). Expressed in melanoma-specific cytotoxic T cell clones (at protein level) (PubMed:9485206). KLRD1-KLRC1 and KLRD1-KLRC2 are differentially expressed in NK and T cell populations, with only minor subsets expressing both receptor complexes (at protein level) (PubMed:20952657).

KLRC1 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

KLRC1 Antibody (C-term) - Images





Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (human cervical epithelial adenocarcinoma cell line) cells labeling KLRC1 with AP8629b at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-rabbit IgG (NK179883) secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm staining on HeLa cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin (PD18466410) at 1/100 dilution (red).The nuclear counter stain is DAPI (blue).

| Jurkat | |
|----------|--|
| 95 72 | |
| 55 | |
| 36 | |
| 28 | |
| 17 | |

Western blot analysis of KLRC1 Antibody (C-term) (Cat. #AP8629b) in Jurkat cell line lysates (35ug/lane). KLRC1 (arrow) was detected using the purified Pab.





All lanes : Anti-KLRC1 Antibody (C-term) at 1:2000 dilution Lane 1: HepG2 whole cell lysates Lane 2: K562 whole cell lysates Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution Predicted band size : 26 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



Anti-KLRC1 Antibody (C-term) at 1:2000 dilution + Jurkat whole cell lysate Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 26 kDa Blocking/Dilution buffer: 5% NFDM/TBST.





Formalin-fixed and paraffin-embedded human kidney carcinoma with KLRC1 Antibody (C-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.



Overlay histogram showing Jurkat cells stained with AP8629b (green line). The cells were fixed with 2% paraformaldehyde (10 min). The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (AP8629b, 1:25 dilution) for 60 min at 37°C. The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(NA168821) at 1/400 dilution for 40 min at 37°C. Isotype control antibody (blue line) was rabbit IgG (1µg/1x10^6 cells) used under the same conditions. Acquisition of >10, 000 events was performed.

KLRC1 Antibody (C-term) - Background

Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. This protein belongs to the killer cell lectin-like receptor family, also called NKG2 family, which is a group of transmembrane proteins preferentially expressed in NK cells. This family of proteins is characterized by the type II membrane orientation and the presence of a C-type lectin domain. This protein forms a complex with another family member, KLRD1/CD94, and has been implicated in the recognition of the MHC class I HLA-E molecules in NK cells.

KLRC1 Antibody (C-term) - References

Brooks,A.G., et.al., J. Exp. Med. 185 (4), 795-800 (1997) Plougastel,B., et.al., Immunogenetics 44 (4), 286-291 (1996)